Healthcare Industry News: ferrous fumarate
News Release - October 3, 2007
Watson Files Application for Generic FEMCON(R) FeParagraph IV Patent Challenge Underway
CORONA, Calif., Oct. 3 (HSMN NewsFeed) -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of FEMCONŽ Fe tablets prior to the expiration of patents owned by Warner Chilcott Company, Inc., a subsidiary of Warner Chilcott Limited. Warner Chilcott, filed suit against Watson on October 1, 2007 in the U.S. District Court of New Jersey, seeking to prevent Watson from commercializing its product prior to the expiration of patent number 6,667,050. Warner Chilcott's suit was filed under the provisions of the Hatch Waxman Act, resulting in a stay of FDA approval of Watson's ANDA for 30 months or until final resolution of the matter before the court, whichever occurs sooner.
FEMCONŽ Fe (norethindrone and ethinyl estradiol tablets, chewable and ferrous fumarate tablets) 0.4mg/35mcg is indicated for the prevention of pregnancy.
Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.
FEMCONŽ Fe is a registered trademark of Warner Chilcott Limited.
Source: Watson Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.